METHOD OF PREDICTING PRODUCTION STABILITY OF CLONAL CELL LINES
The invention relates to a method of predicting production stability and/or production instability of a clonal cell line, the method comprising the steps of a) growing two or more clonal cell lines in separate cell cultures b) karyotyping the cells in each cell culture; and c) deriving a genomic instability value from the karyotyping of step (b). The invention also relates to methods of selecting a cell line which expresses a therapeutic protein and method of selecting a high-titre producing clonal cell line for large scale therapeutic protein production.
1 . A method of predicting production stability and/or production instability of a clonal cell line, the method comprising the steps of
(a) growing two or more clonal cell lines in separate cell cultures
(b) karyotyping the cells in each cell culture; and
(c) deriving a genomic instability value from the karyotyping of step (b).
2 . A method of selecting a cell line which expresses a therapeutic protein, the method comprising the steps of
(a) growing two or more clonal cell lines in separate cell cultures
(b) karyotyping the cells in each cell culture
(c) deriving a genomic instability value from the karyotyping of step (b); and
(d) selecting a clonal cell line based on the genomic instability value of step (c).
3 . A method of selecting a high-titre producing clonal cell line for large scale therapeutic protein production, the method comprising the steps of
(a) growing two or more clonal cell lines in separate cell cultures
(b) karyotyping the cells in each cell culture
(c) deriving a genomic instability value from the karyotyping of step (b); and
(d) selecting a clonal cell line based on the genomic instability value of step (c).
4 . The method of according to claim 2 , wherein karyotyping comprises identifying chromosomal aberrations of the clonal cell lines.
5 . The method according to claim 2 , wherein karyotyping comprises performing multi-colour fluorescence in situ hybridisation (MFISH), spectral karyotyping (SKY) or Giesma banding (G banding).
6 . The method according to claim 2 , further comprising after step (b), the step of determining subpopulations of each cell culture by karyotype.
7 . The method according to claim 6 , wherein deriving the genomic instability value comprises assigning each subpopulation as comprising clonal chromosomal aberration (CCA) or non-clonal chromosomal aberration (NCCA).
8 . The method according to claim 7 , wherein deriving the genomic value further comprises the step of determining a percentage CCA and/or percentage NCCA for each clonal cell line.
9 . The method according to claim 2 , wherein deriving the genomic instability value comprises determining an average matching cost distribution.
10 . The method according to claim 9 , wherein deriving the genomic instability value comprises determining a variance of the average matching cost distribution.
11 . The method according to claim 2 , wherein the genomic instability values are used to i) rank the clonal cells by % CCA or variance of the average matching cost distribution; (ii) derive a % CCA threshold or variance of the average matching cost distribution threshold; and (iii) derive a quartile threshold.
12 . The method according to claim 11 , wherein the genomic instability values are used to derive a % CCA threshold, optionally wherein the % CCA threshold is at least 70%, further optionally wherein the % CCA threshold is 78%.
13 . The method according to claim 2 , wherein the step of karyotyping the cells in each cell culture and/or the step of deriving a genomic instability value from the karyotyping is/are automated.
14 . The method according to claim 13 , wherein automation is computer-implemented automation.
15 . The method according to claim 2 , wherein the step of karyotyping the cells in each cell culture is carried out between 10 generations and 40 generations, optionally wherein the step of karyotyping the cells in each cell culture is carried out after 10, 15 or 20 generations.
16 . The method according to claim 2 , wherein the clonal cell line is a mammalian cell line.
17 . The method according to claim 16 , wherein the mammalian cell line is a Chinese Hamster Ovary (CHO) cell line.
18 . The method according to claim 17 , wherein the CHO cell line is CHO-K1.
19 . The method according to claim 17 , wherein the CHO cell line is a glutamine synthetase (GS) knocked out cell.